MAS related GPR family member X7, pseudogeneGenealiases: []
Q-omics provides the consensus-scored MRGPRX7P profile across patient tissues and cancer cell-line models. MRGPRX7P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, MRGPRX7P is differentially expressed in 9, with the highest sampling consensus in BLCA. Additionally, MRGPRX7P RNA expression shows 6,094 significant pathway-activity associations, with the highest sampling consensus in BRCA. Together, these results highlight OV, BLCA, and BRCA as cancer lineages where MRGPRX7P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRGPRX7P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRGPRX7P survival associations across molecular data types. MRGPRX7P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRGPRX7P RNA expression–survival associations across cancer types. High MRGPRX7P expression shows unfavorable associations in OV, LUSC, READ and THCA, but favorable associations in BRCA and SARC. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for MRGPRX7P RNA expression.
This table summarizes MRGPRX7P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for MRGPRX7P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRGPRX7P shows lower tumor expression in BLCA, COAD, READ, BRCA, STAD and LUSC. The BLCA box plot shows higher MRGPRX7P RNA expression in normal versus tumor tissue (log2 FC = −0.358, t-test p = .001).
This table shows molecular features associated with MRGPRX7P in patient tissues and cancer cell lines. In patient samples, MRGPRX7P shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
